Diabetes
Biolinq's new funding was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.
The Eversense Bridge program is geared toward patients with high-deductible insurance plans or plans that don't cover the full cost of Eversense CGM, and allows them to purchase the system for $99.
The company will augment its BYOD strategy with optional included sensors.
The tool considers vascular changes and individual risk data to make its predictions.
Reactions to the news are mixed, with some experts saying the test is unlikely to make much of a difference.
Users of the Eversense CGM will be able to transfer their data to Glooko's online diabetes management platform.
Dexcom announced a slew of announcements this morning including an integration with Google Fit, a feature that lets users share their readings with 10 people and a technical inquiries feature.
The d-Nav Insulin Guidance Service was also the focus of a multi-center, randomized control trial published last week in the Lancet.
Abbott joins Dexcom, Glooko and Roche as a data-sharing partner for the as-yet-unlaunched device.
This morning Glooko also announced that its diasend platform will be compatible with the Dexcom G6.